UPDATE 1-Novartis says MS drug cut risk of disability advance in study

ZURICH, Sept 17 (Reuters) - Novartis's

investigational multiple sclerosis drug cut the risk of

disability progression in patients with a tough-to-treat form of

the disease versus a placebo, the...

Read more